Retrospective 3,966 COVID-19 patients, 1,115 with cancer, showing lower mortality with remdesivir and higher mortality with convalescent plasma.
risk of death, 240.0% higher, OR 3.40, p < 0.001, treatment 284, control 3,682, adjusted per study, multivariable, day 30, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Raad et al., 26 Aug 2022, retrospective, multiple countries, preprint, 52 authors, study period January 2020 - November 2020.